7506-37-8

Basic information

• Product Name: 2-{[(4-methoxyphenyl)amino]methyl}-1H-isoindole-1,3(2H)-dione
• Synonyms: 1H-isoindole-1,3(2H)-dione, 2-[[(4-methoxyphenyl)amino]methyl]-; 2-[(4-Methoxy-phenylamino)-methyl]-isoindole-1,3-dione
• CAS NO: 7506-37-8
• Molecular Formula: C₁₆H₁₄N₂O₃
• Molecular Weight: 282.294
• Mol File: 7506-37-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 484°C at 760 mmHg
• Flash Point: 246.5°C
• Density: 1.334g/cm³
• Vapor Pressure: 1.6E-09mmHg at 25°C
• Refractive Index: 1.661
• CAS DataBase Reference: 2-{[(4-methoxyphenyl)amino]methyl}-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{[(4-methoxyphenyl)amino]methyl}-1H-isoindole-1,3(2H)-dione(7506-37-8)
• EPA Substance Registry System: 2-{[(4-methoxyphenyl)amino]methyl}-1H-isoindole-1,3(2H)-dione(7506-37-8)

Safety Data

• Hazardous Substances Data: 7506-37-8(Hazardous Substances Data)

Usage

Also known as

Mitomycin C

Classification

Naturally occurring antibiotic and antitumor drug

Category

Antitumor antibiotics (chemotherapy medication)

Origin

Derived from the bacterium Streptomyces caespitosus

Medical use

Treatment of various types of cancer

Cancer types

Stomach, pancreatic, and breast cancer

Mechanism of action

Inhibits the synthesis of DNA and RNA

Outcome

Ultimately leading to the destruction of cancer cells

Administration

Commonly administered intravenously

Combination therapy

May be used with other chemotherapy drugs

Side effects

Potential for severe side effects, including bone marrow suppression and kidney damage

Patient monitoring

Important for patients to be closely monitored by a healthcare professional while receiving this medication

Upstream product

• 136918-14-4 phthalimide 
• 50-00-0 formaldehyd 
• 104-94-9 4-methoxy-aniline 

Relevant articles and documents

Isoindole-1,3-dione derivatives as RSK2 inhibitors: Synthesis, molecular docking simulation and SAR analysis

RSK2 (p90 ribosomal S6 kinase 2) is a serine/threonine kinase expressed in a variety of cancers. Molecular-targeted inhibition of RSK2 as a potential therapeutic strategy for human cancers has been documented. In this work, a series of isoindole-1,3-dione derivatives as novel RSK2 inhibitors were designed and synthesized from a hit discovered in our previous study. Some compounds were confirmed to be moderately potent RSK2 inhibitors with IC50 values of about 0.5 μM. Structure-activity relationship analysis and binding mode studies by molecular docking were performed.